VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 20, 2007) - Pyng Medical Corp. (the "Company") (TSX VENTURE:PYT) announces that it has granted an incentive stock option to an officer of the Company under its Stock Option Plan to purchase up to 50,000 common shares in its capital stock exercisable at a price of $0.50 per share, subject to all necessary approvals. The option granted is exercisable for a period of 2 years expiring on September 12, 2009.
About Pyng Medical Corp.
Pyng Medical Corp. is a world-leader in intraosseous infusion with its proprietary award-winning FAST1(TM) Intraosseous Infusion System. The FAST1(TM) is used extensively by the U.S. Department of Defense and by Emergency Medical Services around the globe.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.
FOR FURTHER INFORMATION PLEASE CONTACT:
Pyng Medical Corp.